NCT03199040
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03199040
Title Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Washington University School of Medicine
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field